Abstract:Background: In the past two decades, a large-scale survey of hemoglobinopathies and thalassemia was carried out in mainland China, involving nearly one million people in 28 provinces. The incidences of hemoglobin (Hb) variants, α-thalassemia and β-thalassemia were 0.33%, 2.64% and 0.66%, respectively. The chemical structural analysis identified 67 Hb variants. Among them, 20 are new variants. The analysis of the α-globin gene organization in 111 HbH patients showed 76 cases (68.5%) were of the deletion type, 8 had Hb Constant Spring and the other cases were of non-deletion type. The results of the molecular characterization of more than 200 β-thalassemia alleles showed that the most common types of β-thalassemia mutations in China are CD 41/42 (−4 bp), IVS-II-nt.654 C→T, CD 17 A→T, CD 71/72 (+A) and −28 A→G. Methods: To explore the simple method for molecular diagnosis of β-thalassemia, multiplex allele-specific amplification (MAS-PCR) was used that could simultaneously detect the above five common types of β-thalassemia mutations. Results: Based on the molecular analysis of β-thalassemia intermedia, β-thalassemia homozygotes or compound heterozygotes combined with α-thalassemia, as well as the conjunctive abnormalities of β-thalassemia heterozygote with triplicated haplotype of α-globin genes, were the most common cause of thalassemia intermedia in China. We also used the RT-PCR quantitation method to show that the most common β-thalassemia allele, IVS-II-nt.654 C→T, still produced a small amount (about 15%) of normally spliced β-globin mRNA, therefore, causing β+-thalassemia. In clinical trials of hydroxyurea (HU) treatment for β-thalassemia patients, we found that HU may enhance the expression of the β-globin gene in some patients, leading to an alleviation of clinical symptoms. In the studies of the reversal of aberrant splicing of IVS-II-nt.654 C→T allele by the antisense approach, we constructed a mammalian expression vector that can produce an antisense RNA targeting against the aberrant splice sites of IVS-II-nt.654 C→T pre-mRNA. Conclusions: The results indicated that the antisense RNA produced from the vector could efficiently suppress the aberrant splicing pattern and restore the correct splicing pathway in vitro and in vivo, leading to the improvement of globin chain biosynthesis in thalassemia cells.

Construction of Antisense RNA Expression Vectors and Correction of Splicing Defect in Human Β-Globin Gene (IVS-2-654 C→T Mutant) in HeLa Cells

Repair of Thalassemic Human Β-Globin Mrna in Cultured Erythroid Cells by Antisense RNA

Reversal of Aberrant Splicing of Beta-Thalassaemia Allele (Ivs-2-654 C -> T) by Antisense Rna Expression Vector in Cultured Human Erythroid Cells

Restoration of correct βIVS2-654-globin mRNA splicing and HbA production by engineered U7 snRNA in β-thalassaemia/HbE erythroid cells

Correction of Β 654 -Thalassaemia Mice Using Direct Intravenous Injection of Sirna and Antisense RNA Vectors

High-level Expression of Hemoglobin A in Human Thalassemic Erythroid Progenitor Cells Following Lentiviral Vector Delivery of an Antisense Snrna

Amelioration of Β654-Thalassemia in Mouse Model with the Knockdown of Aberrantly Spliced Β-Globin Mrna

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Treatment of β 654 -thalassaemia by TALENs in a mouse model.

Editing Aberrant Splice Sites Efficiently Restores Β-Globin Expression in Β-Thalassemia

Correction of RNA splicing defect in β654-thalassemia mice using CRISPR/Cas9 gene-editing technology.

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Restoration of the Balanced Alpha/Beta-Globin Gene Expression in Beta(654)-Thalassemia Mice Using Combined Rnai and Antisense Rna Approach

Gene Editing of the Endogenous Cryptic 3' Splice Site Corrects the RNA Splicing Defect in the β654-Thalassemia Mouse Model

In situ correction of various β-thalassemia mutations in human hematopoietic stem cells

The Studies of Hemoglobinopathies and Thalassemia in China--the Experiences in Shanghai Institute of Medical Genetics.

A Transgenic Mouse Model for Dna/Rna Gene Therapy of Human Beta Thalassemia

Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice

RNA Transcripts of the Β‐thalassaemia Allele IVS‐2–654 C → T: a Small Amount of Normally Processed Β‐globin Mrna is Still Produced from the Mutant Gene

Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia

Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients

Construction of Antisense RNA Expression Vectors and Correction of Splicing Defect in Human Β-Globin Gene (IVS-2-654 C→T Mutant) in HeLa Cells

Repair of Thalassemic Human Β-Globin Mrna in Cultured Erythroid Cells by Antisense RNA

Reversal of Aberrant Splicing of Beta-Thalassaemia Allele (Ivs-2-654 C -> T) by Antisense Rna Expression Vector in Cultured Human Erythroid Cells

Restoration of correct βIVS2-654-globin mRNA splicing and HbA production by engineered U7 snRNA in β-thalassaemia/HbE erythroid cells

Correction of Β 654 -Thalassaemia Mice Using Direct Intravenous Injection of Sirna and Antisense RNA Vectors

High-level Expression of Hemoglobin A in Human Thalassemic Erythroid Progenitor Cells Following Lentiviral Vector Delivery of an Antisense Snrna

Amelioration of Β654-Thalassemia in Mouse Model with the Knockdown of Aberrantly Spliced Β-Globin Mrna

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology

Treatment of β 654 -thalassaemia by TALENs in a mouse model.

Editing Aberrant Splice Sites Efficiently Restores Β-Globin Expression in Β-Thalassemia

Correction of RNA splicing defect in β654-thalassemia mice using CRISPR/Cas9 gene-editing technology.

Correction of RNA splicing defect in β&lt;sup&gt;654&lt;/sup&gt;-thalassemia mice using CRISPR/Cas9 gene-editing technology

Restoration of the Balanced Alpha/Beta-Globin Gene Expression in Beta(654)-Thalassemia Mice Using Combined Rnai and Antisense Rna Approach

Gene Editing of the Endogenous Cryptic 3' Splice Site Corrects the RNA Splicing Defect in the β654-Thalassemia Mouse Model

In situ correction of various β-thalassemia mutations in human hematopoietic stem cells

The Studies of Hemoglobinopathies and Thalassemia in China--the Experiences in Shanghai Institute of Medical Genetics.

A Transgenic Mouse Model for Dna/Rna Gene Therapy of Human Beta Thalassemia

Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice

RNA Transcripts of the Β‐thalassaemia Allele IVS‐2–654 C → T: a Small Amount of Normally Processed Β‐globin Mrna is Still Produced from the Mutant Gene

Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia

Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients

Correction of RNA splicing defect in β<sup>654</sup>-thalassemia mice using CRISPR/Cas9 gene-editing technology